|
Rockwell Medical, Inc. (NASDAQ:RMTI) Brokerage Rating Update - Investor Newswire |
|
Rockwell Medical, Inc. (NASDAQ:RMTI) has been handed a rating of 2 on a consensus basis by Zacks Research. Using a simplified 1 to 5 scale where 5 represents a Strong Sell and 1 a Strong Buy, 4 analysts polled by Zacks had their ratings weighed into this average. In order to measure the direction of the analyst sentiment, the same analysts had a rating of 2 on the equity three months ago.
Sell-side analysts covering Rockwell Medical, Inc. (NASDAQ:RMTI) have a one year price average objective of $16.25 on the equity. The targets range from $4 to $26, according to the data from research firms surveyed by Zacks.
Earnings in Focus Analysts on the Street are anticipating Rockwell Medical, Inc. will report earnings per share of $-0.1 for the fiscal quarter ending on 2015-06-30. Estimates from 4 brokers were taken into consideration to arrive at this estimate. Looking ahead on a three to five year basis, Wall Street is expecting earnings of $25 per share on the stock. This is the best estimate according to Zacks for sales and earnings over that time span. Investors and analysts alike will be marking their calendars when Rockwell Medical, Inc. is expected to report earnings on 2015-07-30. The company will be trying to improve on the previous quarter’s numbers of $-0.07 for the quarter ending on 2015-03-31. The actual EPS was 30% away from what analysts had expected, or a $0.03 difference. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patient’s bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.
|
|
|
NxStage Medical, Inc. (NASDAQ:NXTM) Analyst Rating Update - Investor Newswire |
|
Wall Street analysts polled by Zacks Research have given NxStage Medical, Inc. (NASDAQ:NXTM) a rating of 2 on a consensus basis. Using a simplified scale where 1 is a Strong Buy and 5 a Strong Sell, this is the average number of the 4 brokerages surveyed. The stock had a rating of 2 when analyst ratings were averaged three months ago.
The covering analysts have a one year price objective of $21 on NxStage Medical, Inc. (NASDAQ:NXTM). The most bullish brokerage firm sees the stock heading to $24 , while the most conservative estimate has an objective of $15.
Earnings Look Wall Street will be paying close attention when NxStage Medical, Inc. reports their next quarterly earnings report on 2015-08-06. Analysts polled by Zacks are expecting earnings per share of $-0.1 for the period ending 2015-06-30. This is the consensus number based on the 4 broker predictions taken into consideration. On a longer term basis, sell-side analysts who project long term growth are expecting earnings of $18.33. This is the three to five year estimate for both earnings and sales. Most recently NxStage Medical, Inc. reported actual earnings of $0 per share for the quarter ending on 2015-03-31. The actual reported number was $0.11 away from what analysts had expected, yielding a surprise factor of 100%. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Company’s primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.
|
|
Discover the dialysis market - hemodialysis peritoneal dialysis - global ... - WhaTech |
|
- Advertisement -
Dialysis Market @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=1279
A number of factors such as the increasing number of ESRD patients and the rising prevalence of diabetes and hypertension are driving the growth of the global market. Furthermore, growth in the number of dialysis facilities in developed as well as developing economies, growth in aging population, and increasing private investments and venture funding to support new product development are some of the other factors that are propelling the growth of the dialysis products and services market.
In addition, increasing adoption of new treatment modalities such as home hemodialysis and nocturnal dialysis is further fuelling the growth of this market.
However, a few pivotal factors such as the reduction in Medicare reimbursements to dialysis centers, low awareness about kidney diseases and their treatment modalities, product recalls, reuse of hemodialysis supplies, and poor reimbursement scenario in developing countries are hindering the growth of this market. Moreover, high competition among market players and low cost of kidney transplantation are the foremost challenges faced by industry players.
Customization Option Available @ http://www.marketsandmarkets.com/requestCustomization.asp?id=1279
The global market is dominated by North America, followed by Asia-Pacific, Europe, and Rest of the World (RoW). North America will continue to dominate the market in the forecast period, followed by Asia-Pacific.
However, the Asia-Pacific region is expected to grow at the highest CAGR of ~9.7% from 2013 to 2018. Over the next five years, the growth of the dialysis products and services market in the Asia-Pacific region is likely to be centered at Japan, China, South Korea, and India.
A number of factors such as the huge patient population base, increasing number of dialysis centers, improving reimbursement and insurance scenario, and increasing government initiatives to develop dialysis facilities are driving the growth of the market in the Asia-Pacific region.
Partnerships, agreements, collaborations, and joint ventures are the key strategies followed by leading market players, to ensure their growth in the market. The introduction of bundle reimbursement system has further increased the number of collaborative partnerships among market players.
Mergers and acquisitions, expansions, and new product launch are some of the other growth strategies adopted by industry players in the global market.
The global products and services market is dominated by Fresenius Medical Care AG & Co. KGaA (Germany), DaVita Healthcare Partners, Inc. (U.S.), Gambro AB (Sweden), Baxter International, Inc. (U.S.), B. Braun Melsungen AG (Germany), Nipro Corporation (Japan), Diaverum Deutschland GmbH (Germany), Medical Components, Inc. (U.S.), Covidien (Ireland), and NxStage Medical, Inc. (U.S.) < Prev Next >
|
|
S-1 Plus Sorafenib May Be Safe, Effective for Renal Cell Carcinoma - Cancer Therapy Advisor |
June 29, 2015
Combination therapy with S-1 plus sorafenib is effective and tolerable as treatment for patients with metastatic renal cell carcinoma.
Combination therapy with S-1 plus sorafenib is effective and tolerable as treatment for patients with metastatic renal cell carcinoma, a new study published online ahead of print in the journal Annals of Oncology has shown.
For the single-arm, open-label, phase 1/2 study, researchers sought to evaluate the clinical activity, safety, tolerance, and pharmacokinetics of S-1 plus sorafenib in patients with metastatic renal cell carcinoma.
Researchers enrolled nine patients into phase 1 and 21 patients into phase 2. Of those 21, six had received the recommended dose in phase 1. All participants were diagnosed with clear-cell or papillary renal cell carcinoma who had received no more than one prior cytokine-based regimen.
The recommended dose of therapy was S-1 80 mg/m2/day on days 1 to 28 with sorafenib 800 mg/day on days 1 to 42.
Results showed that among the 21 evaluable patients in phase 2, the confirmed overall response rate was 52% (95% CI: 29.8, 74.3). One patient achieved a complete response and 10 patients achieved partial responses.
Researchers found that median progression-free survival was 9.9 months (95% CI: 6.5, 17.1).
RELATED: Functional Adaptive Hyperfiltration May Affect Renal Function after Radical Nephrectomy
In regard to safety, all patients experienced treatment-related hand-foot skin reactions, which resulted in dose reductions in 38% of patients.
The findings suggest that although S-1 and sorafenib combination therapy appears to be effective and tolerable for patients with metastatic renal cell carcinoma, skin event management is necessary for patients receiving this therapy.
Reference
- Naito S, Sakai H, Hashine K, et al. Phase 1/2 study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.Ann Oncol. 2015. [epub ahead of print]. doi: 10.1093/annonc/mdv280.
|
|
BJP demands probe into 'dog dialysis' at Bengal hospital - Big News Network.com |
Union minister and BJP leader Sanjeev Balyan on Monday demanded a probe into allegations of arrangements being made for a dog to undergo dialysis at West Bengal's government-run SSKM Hospital.
Pradip Mitra, who was recently transferred from the post of SSKM director, claimed he was handed over marching orders for stopping the dialysis of a dog at the premier hospital on June 10.
The dog was allegedly sent for treatment by Trinamool Congress leader Nirmal Majhi, who heads the state medical council.
Terming his transfer to the College of Medicine and Sagore Dutta Hospital as an "insult", Mitra applied for voluntary retirement and also threatened to move court.
"If an order for a dog's dialysis was really made, then it is very unfortunate. The matter must be probed and strict action taken against those found guilty," said Balyan, the union minister of state for agriculture.
During the day, BJP leader Locket Chatterjee also submitted a memorandum to new SSKM director Manju Banerjee seeking details about the incident.
"People have the right to know the truth. Who ordered the arrangements for the dog's dialysis and at whose insistence? The hospital must come clean on this. An independent probe into the matter is imperative," Chatterjee, who is also a famed Bengali actress, told media persons.
Trinamool legislator Majhi has repeatedly denied the allegations and accused the media of defaming him.
|
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
